Ascenion, the knowledge and technology transfer partner of the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), has negotiated an agreement with Roche Diagnostics (F. Hoffmann-La Roche Ltd), providing the company with an option to receive exclusive rights to use proprietary nanoparticles for in-vitro diagnostic applications. The particles were generated at first at the University of Münster, then functionalized and characterized in a collaborative effort by HZDR and researchers of the University of Münster.
With sizes in the low nanometer range, they show small-molecule-like pharmacokinetics in in-vivo model systems. This, together with their biocompatibility and surface functionalization, opens up a broad range of further applications in nanomedicine, including clinical research, in-vivo diagnosis and the treatment of diseases.
Ascenion has been working with the inventors of both institutions, University of Münster and HZDR, for several years supporting the patent application and commercialization of their approach.
For further information:
Website HZDR